Day: December 5, 2021

First and only neutralizing antibody therapy for this age group SHANGHAI, China, Dec. 06, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the United States Food and Drug Administration (the “FDA”) has expanded the emergency use authorization (“EUA”) for etesevimab (JS016/LY-CoV016) and bamlanivimab (LY-CoV555) administered together (the “Therapy”) to include certain high-risk pediatric patients from birth to under 12 years old for the treatment of mild to moderate COVID-19 as well as post-exposure prophylaxis, according to Eli Lilly and Company (“Lilly”), the company’s global partner. The Therapy has been the first and only authorized neutralizing antibody...

A representative of novel MPro inhibitor series, MPI8, dually inhibits MPro and cathepsin L, a key viral entry enzyme, with high potency and selectivity. Other analogs of the series have been evaluated by Sorrento to develop an oral antiviral drug for treatment of patients infected with existing and emerging SARS-CoV-2 variants of concern, including Omicron. A promising candidate of the series with unique features distinguished from SARS-CoV-2 MPro inhibitors published by others has been systematically evaluated and advanced to late stage of pre-clinical phase.SAN DIEGO, Dec. 05, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors with potent activities for both MPro and cathepsin L, a key host enzyme for...

Bavarian Nordic’s non-adjuvanted COVID-19 vaccine candidate, ABNCoV2 (100μg), demonstrated a strong boosting effect, increasing the existing levels of SARS-CoV-2 neutralizing antibodies against the Wuhan variant by 2-40-fold depending on the initial levels of antibodies The large boosting effect of ABNCoV2 elevated the neutralizing antibodies to levels reported to be highly efficacious (>90%) against SARS-CoV-21 A similar fold increase was observed for all SARS-CoV-2 variants tested (Wuhan, Alpha, Beta and Delta) following the booster vaccination with ABNCoV2 The vaccine was well-tolerated, with no serious adverse events reported These initial results confirm the potential of ABNCoV2 to function as a universal COVID-19 booster vaccine The Company’s management will host a conference call tomorrow at 2 pm CET (8 am EST) to discuss the resultsCOPENHAGEN,...

San Francisco, California, USA., November 30, 2021 – Following its rapid expansion over the past 24 months, US Capital Global now operates from 13 offices in 10 countries. The group’s global presence allows it to provide the best customized financial and investment solutions for its clients, often by breaking through international barriers that have traditionally hampered the industry. The upshot of this expansion across four continents is, of course, increased diversity in its investment officers, support staff, clients, and partners. As a global group serving global clients, US Capital Global prides itself on its diversity. Each of its office locations is driven by a strong team sharing different ethnicities, nationalities, genders, religions, education, and political outlooks, and yet united by a deep-rooted company culture of...